← Scroll for more →
Financial Statements — GP
Balance Sheet
(in millions USD)| Metric | Q3 2024 | Q1 2024 | Q3 2023 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0.12 | 1.15 | 1.99 | 0.60 | 6.89 |
| Inventory | 31.72 | 32.01 | -- | 41.61 | -- |
| Total Current Assets | 33.21 | 36.85 | -- | 54.16 | -- |
| Total Non-current Assets* | 6.16 | 8.35 | -- | 9.37 | -- |
| Total Assets | 39.37 | 45.20 | -- | 63.53 | -- |
| Total Current Liabilities | 23.12 | 21.29 | -- | 26.50 | -- |
| Total Non-current Liabilities* | 12.10 | 12.34 | -- | 9.36 | -- |
| Total Liabilities | 35.22 | 33.64 | -- | 35.86 | -- |
| Retained Earnings | (88.95) | (79.02) | -- | (60.79) | -- |
| Total Stockholder Equity | 4.15 | 11.57 | 22.35 | 27.66 | 34.39 |
← Scroll for more columns →
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|
| Total Revenue | 7.22 | 5.35 | 3.00 | 8.16 | 8.44 | 17.58 | 12.80 |
| Cost of Revenue* | 6.16 | 4.89 | 2.78 | 6.80 | 7.21 | 14.79 | 10.58 |
| Gross Profit | 1.05 | 0.46 | 0.22 | 1.35 | 1.23 | 2.79 | 2.22 |
| Research & Development | 0.38 | 0.40 | 0.23 | 0.44 | 0.32 | 0.81 | 0.62 |
| Total Operating Expenses | 5.23 | 4.58 | 5.13 | 5.68 | 5.22 | 5.32 | 5.21 |
| Interest Expense | 0.56 | 0.57 | 0.52 | 0.34 | 0.27 | 0.28 | 0.47 |
| Net Income | (4.74) | (4.70) | (5.39) | (4.64) | (4.26) | (2.81) | (3.38) |
| Basic EPS | (0.17) | (0.18) | (0.21) | (0.19) | (0.17) | (0.11) | (0.14) |
| Diluted EPS | (0.17) | (0.18) | (0.21) | (0.19) | (0.17) | (0.11) | (0.14) |
← Scroll for more columns →
* Derived from reported values
Cash Flow Statement
(in millions USD)| Metric | Q2 2024 | Q2 2023 |
|---|---|---|
| Operating Cash Flow | (3.21) | 7.76 |
| Investing Cash Flow | (0.05) | (0.03) |
| Financing Cash Flow | 2.64 | (6.86) |
← Scroll for more columns →